Palmitoyl Tripeptide-8 (Neuroskin) (CAS 936544-53-5) is supplied by TCS NEXUS S.L. (Valencia, Spain) for European cosmetic formulators, brand R&D teams and B2B buyers reviewing cosmetic peptide raw material applications. With limited direct water solubility, it requires propylene glycol or ethanol pre-dispersion before aqueous dilution, at pH 4.5–7.0, with incorporation below 40°C in standard emulsion manufacturing protocols.
> Technical Specifications
| Product Name | Palmitoyl Tripeptide-8 (Neuroskin) |
|---|---|
| Molecular Structure |  |
| CAS Number | 936544-53-5 |
| Alias / Common Name | Palmitoyl Tripeptide-8; Neuroskin; NK1R-targeting neuro-calming lipopeptide |
| Molecular Formula | C37H61N9O4 |
| Molecular Weight | 695.9 g/mol |
| INCI Name | Palmitoyl Tripeptide-8 |
| Peptide Sequence | Palmitoyl-GHK (C16 palmitoyl-Gly-His-Lys) — NK1R-targeted neuro-calming lipopeptide |
| Functional Class | Synthetic lipopeptide; NK1R (neurokinin-1 receptor / substance P receptor) modulator; neuro-inflammatory pathway active; sensitive-skin and reactive skin barrier peptide |
| Purity / Assay | ≥98% (HPLC); confirm by batch COA |
| Appearance | White to off-white powder |
| Solubility / Handling | Lipopeptide; limited direct water dispersibility. Pre-disperse in propylene glycol (5–15%) or ethanol (10–20%) before adding to the aqueous phase at cool-down below 40°C. |
| pH Stability | Optimal stability at pH 4.5–7.0. Confirm stability in the complete formulation base. |
| Storage | Store sealed below 25°C in a cool, dry location protected from direct light and moisture. Follow SDS and batch COA conditions. |
> Mechanism & Positioning
Palmitoyl Tripeptide-8 (Neuroskin) is a synthetic lipopeptide designed to modulate neurogenic inflammation in sensitised skin through NK1R (neurokinin-1 receptor) pathway antagonism. Published Palmitoyl Tripeptide-8 literature discusses competitive interaction at NK1R — the substance P receptor expressed on dermal mast cells, endothelial cells and resident immune cells — reducing substance P-mediated mast cell degranulation and histamine release. Cell-based mast cell and sensory co-culture studies document reduced cytokine secretion (IL-6, TNF-α) and attenuated degranulation index following Palmitoyl Tripeptide-8 treatment. Reactive skin explant model data also notes decreased erythema scores and reduced neuropeptide-driven vasodilation in ex vivo sensitised skin models. The C16 palmitoyl anchor facilitates membrane association and may increase local peptide concentration at the skin surface lipid layer, supporting sustained receptor availability in the target tissue.
Palmitoyl Tripeptide-8 builds a two-node neuro-calming system with Acetyl Tetrapeptide-15 (Skinasensyl) — targeting TRPV1 upstream while Palmitoyl Tripeptide-8 targets NK1R downstream. For comprehensive barrier-plus-neuro sensitive skin formats, add Acetyl Dipeptide-1 Cetyl Ester for TJ reinforcement and Ectoin for extremolyte membrane stabilisation. Contact info@tcspeptides.com with formulation specification.
> Application Concepts
Sensitive-Skin Emulsion and Neuro-Lipopeptide Architecture
Palmitoyl Tripeptide-8 at 0.001–0.05% integrates into emulsions, cream-gels and serum-in-oil formats targeting reactive and sensitised skin. The palmitoyl anchor requires PG pre-dispersion (5–15% PG, 40–50°C, gentle stirring) before addition to the aqueous or emulsion phase during cool-down below 40°C. Do not add undispersed powder directly to hot aqueous phases. For emulsion formats, add the PG dispersion to the emulsifier blend or cream base at 35–40°C during cool-down. For aqueous serum formats, add the PG dispersion to the completed water phase at room temperature. Evaluate alongside bisabolol (0.1–0.5%), panthenol (1–3%) and allantoin (0.1%) for multi-ingredient calming positioning.
NK1R Pathway vs TRPV1 Pathway — Targeting Substance P Upstream and Downstream
Neurogenic skin inflammation involves a substance P signalling axis: sensory nerve activation → substance P release → NK1R binding on mast cells → degranulation → cytokine/histamine cascade. TRPV1 channel activation (heat, capsaicin, acid) is one upstream trigger for substance P release; Acetyl Tetrapeptide-15 addresses this upstream step. Palmitoyl Tripeptide-8 addresses the downstream NK1R effector step. Combining both peptides blocks the substance P axis at two non-redundant nodes — upstream stimulus transduction and downstream receptor activation — creating a comprehensive anti-neurogenic-inflammation strategy for severe reactive skin, rosacea-prone skin and post-inflammatory conditions. Evaluate each peptide individually before combining to establish dose-response baselines.
Rosacea, post-procedure and Environmentally Sensitised Skin Format Applications
Palmitoyl Tripeptide-8 is positioned for three high-value sensitised-skin market segments: rosacea and chronic erythema (substance P-driven vasodilation and mast cell axis), post-procedure and post-peel recovery (neurogenic inflammation from tissue disruption), and environmentally sensitised skin (pollution and UV-triggered sensory axis activation). In rosacea formats, NK1R antagonism addresses the substance P-driven erythema and flushing cycle without the irritancy risk of retinoids or high-concentration acids. In post-procedure recovery, reduction in substance P-mediated histamine release supports faster resolution of post-procedure redness and sensory hypersensitivity. All three applications benefit from combining Palmitoyl Tripeptide-8 with antioxidants such as Ergothioneine to address the oxidative stress component of sensitised-skin pathology.
> Handling & Formulation Notes
Pre-disperse Palmitoyl Tripeptide-8 in propylene glycol (5–15 parts PG per 1 part peptide) at 40–50°C with gentle stirring until uniform dispersion is achieved before incorporation into the formulation. For emulsion formats, add the PG dispersion to the emulsifier blend or cream base during cool-down at 35–40°C. For aqueous serum formats, add the PG dispersion at cool-down below 40°C to the completed water phase. Avoid prolonged exposure above 45°C to prevent palmitoyl amide bond degradation.
Confirm stability of Palmitoyl Tripeptide-8 (Neuroskin) in the complete formulation at 40°C/75% RH for 12 weeks before scale-up. Monitor lipopeptide integrity by HPLC if formulating at pH outside 4.5–7.0 or in high-electrolyte bases. Follow SDS and batch COA for storage and handling; confirm shelf life for the specific batch.
> Supply & Documentation
Palmitoyl Tripeptide-8 (Neuroskin) (CAS 936544-53-5) is available from TCS NEXUS S.L. (Valencia, Spain) for B2B cosmetic raw material projects. Standard documentation: COA, TDS, SDS. Sample and bulk quantities are discussed on a per-project basis; contact info@tcspeptides.com to initiate a sourcing review.
TCS NEXUS S.L. supports procurement and formulation teams in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, Poland, Sweden and Portugal, as well as international buyers in the United States, Canada, Japan, South Korea, Australia and New Zealand.
> Packaging & Storage
Palmitoyl Tripeptide-8 (Neuroskin) is supplied in sealed aluminium foil bags or bulk containers. Minimum quantities and packaging configurations are confirmed per order. Store below 25°C in a cool, dry location, away from moisture and direct light. Follow batch COA and SDS for specific storage and handling conditions.
> FAQ
What is Palmitoyl Tripeptide-8 (Neuroskin)?
Palmitoyl Tripeptide-8 (Neuroskin) (CAS 936544-53-5) is a cosmetic raw material supplied by TCS NEXUS S.L. (Valencia, Spain) for B2B cosmetic formulators. In cosmetic literature, Palmitoyl Tripeptide-8 (Neuroskin) is positioned as a neurocalming lipopeptide that reduces neuropeptide-induced cutaneous inflammation — evaluated in sensitive-skin, reactive-skin and redness-reduction formulations where neurogenic inflammation drives discomfort and visible redness. TCS NEXUS S.L. supplies Palmitoyl Tripeptide-8 as a B2B active for formulators developing calming and anti-reactive leave-on products.
What is the CAS number for Palmitoyl Tripeptide-8 (Neuroskin)?
The CAS number for Palmitoyl Tripeptide-8 (Neuroskin) is 936544-53-5. The INCI name for cosmetic regulatory documentation and CPNP notification is Palmitoyl Tripeptide-8; confirm CAS 936544-53-5 and INCI identity against the batch COA when building product files.
How does Neuroskin calm reactive skin — what is the NK1R / substance-P mechanism?
Palmitoyl Tripeptide-8 (Neuroskin) is a palmitoylated GHK-type lipopeptide discussed as a modulator of the NK1R (neurokinin-1) receptor, the receptor for substance P that drives neurogenic redness and reactivity. By tempering that substance-P signalling it is positioned to restore comfort and reduce the look of reactivity in sensitive, redness-prone skin. The palmitoyl chain provides lipophilicity for delivery.
What use level of Neuroskin is typical, and how should it be evaluated?
Because the effective level shifts with formulation and claim, build it up conservatively from your own evaluation instead of fixing on one number; it is usually a trade solution, so confirm your dosing basis. We supply the pure material with COA — contact info@tcspeptides.com to align documentation.
Which actives pair with Neuroskin in a redness-calming system?
Neuroskin (NK1R/substance-P pathway) is complementary to Acetyl Tetrapeptide-15 (Skinasensyl, TRPV1) — the two cover different neuro-sensory routes — and it combines with soothing actives, niacinamide and barrier lipids for redness-prone skin. As a lipopeptide it needs pre-dispersion; confirm clarity and pH in the finished base.
What makes Neuroskin distinct — the NK1R / substance-P focus?
Its distinctive target is the NK1R substance-P receptor behind neurogenic redness, different from the TRPV1 irritant channel that Skinasensyl modulates — which is why the two are combined for broad sensitive-skin coverage. As a palmitoylated lipopeptide it has limited water solubility and is pre-dispersed before use.
What addition temperature is recommended for Palmitoyl Tripeptide-8 (Neuroskin) during manufacturing?
Introduce Palmitoyl Tripeptide-8 (Neuroskin) during the cool-down phase at temperatures below 40°C; avoid prolonged exposure above this threshold. Standard aqueous or emulsion cool-down protocols are fully compatible with this addition requirement. Confirm thermal stability in the specific manufacturing process with accelerated stability data before committing to production scale.
What pH range keeps Neuroskin stable in a finished formula?
Palmitoyl Tripeptide-8 is most stable at roughly pH 4.5–7.0; confirm the finished-product pH after all actives are incorporated and evaluate combined stability in the complete base.
Is Palmitoyl Tripeptide-8 (Neuroskin) compatible with other actives in multi-active cosmetic systems?
Palmitoyl Tripeptide-8 (Neuroskin) is compatible with standard cosmetic actives at pH 4.5–7.0 in aqueous or emulsion systems. Evaluate combined system pH drift, clarity and assay retention; confirm preservative compatibility. Run accelerated stability testing at 40°C/75% RH before scale-up.
Is Palmitoyl Tripeptide-8 (INCI) compliant with EU Cosmetics Regulation 1223/2009?
Palmitoyl Tripeptide-8 is not listed as a restricted, prohibited or regulated substance under EU Cosmetics Regulation 1223/2009 Annexes II–VI. The finished product manufacturer is responsible for the CPSR and CPNP notification. Use CAS 936544-53-5 and INCI name Palmitoyl Tripeptide-8 consistently in all regulatory documentation; confirm purity and identity against the batch COA.
How should Palmitoyl Tripeptide-8 (Neuroskin) be stored?
Store Palmitoyl Tripeptide-8 (Neuroskin) sealed below 25°C in a cool, dry location protected from direct light and moisture. Once opened, reseal the container immediately. Follow specific storage and handling conditions stated in the SDS and batch COA. Confirm shelf life for the specific batch before incorporating into production formulations.
What documentation does TCS NEXUS S.L. provide for Palmitoyl Tripeptide-8 (Neuroskin)?
TCS NEXUS S.L. provides COA (confirming CAS 936544-53-5 and HPLC purity ≥98% (HPLC)), TDS (Technical Data Sheet) and SDS (Safety Data Sheet) for Palmitoyl Tripeptide-8 (Neuroskin). Additional documentation such as specification sheets and INCI confirmation letters is available on a per-project basis. Contact info@tcspeptides.com to initiate a documentation and sourcing discussion.
What MOQ and sample options are available for Palmitoyl Tripeptide-8 (Neuroskin)?
Sample and bulk quantities for Palmitoyl Tripeptide-8 (Neuroskin) are confirmed on a per-project basis through TCS NEXUS S.L. Minimum order quantities depend on current stock, packaging configuration and project scope. R&D teams are encouraged to request samples for stability and concentration-range evaluation before bulk planning. Contact info@tcspeptides.com with project specification to begin a sourcing review.
> Technical Support and Samples
Request COA documents, sample availability, or support for custom synthesis.